SGS S.A.

SGS reported H1 2026 sales of CHF 3.7 billion, with organic growth of 5.6% and constant-currency sales growth of 13.4% including 7.8% from M&A. Adjusted operating income margin was 15.1%, up 20 basis points, and free cash flow was CHF 260 million, up 25% excluding proceeds from last year’s Geneva headquarters disposal. EPS reached CHF 1.58, up 14.5% on the adjusted comparison management provided. By business line, organic growth was 4.7% in Industries & Environment, 5.5% in Natural Resources, 6.8% in Connectivity & Products, 4.5% in Health & Nutrition, and 7.3% in Business Assurance. Management confirmed full-year guidance and said H1 restructuring costs were CHF 18 million, with about CHF 30 million expected for the full year, still within the CHF 20 million to CHF 40 million range previously given. They also said net debt/EBITDA should be around 2.2x at December and that free cash flow seasonality is roughly one-third in H1 and two-thirds in H2.

Geraldine Picaud framed the first half as proof that SGS’s Strategy 27 is working, emphasizing execution across digital trust, sustainability, ATS, and bolt-on acquisitions. She said Digital Trust grew 38% overall, Sustainability/IMPACT NOW grew 18% overall, and ATS is already generating cost savings and cross-selling opportunities such as the new data-center offering. Her tone was confident and resilient, repeatedly stressing that SGS can offset external shocks like the Middle East situation and still deliver its guidance.

Marta Vlatchkova focused on the mechanics of the H1 numbers: sales of CHF 3.7 billion, adjusted operating income margin of 15.1%, EPS of CHF 1.58, and free cash flow of CHF 260 million. She said the margin improvement came from CHF 39 million of organic operating income growth and CHF 42 million from M&A, partly offset by a CHF 35 million negative FX impact from the strong Swiss franc. She also said H1 restructuring costs were CHF 18 million, full-year restructuring should be around CHF 30 million, financial expenses should not rise significantly in H2, and year-end leverage should be around 2.2x adjusted EBITDA.

Analysts focused on ATS margins and EBITDA, unbilled revenue/WIP, restructuring charges tied to the Middle East, North America and Natural Resources acceleration, Europe softness, leverage, and whether bolt-on M&A will continue. Management said ATS is on plan, with EBITDA referenced by the analyst as $98 million and the business slightly accretive to group margins; Maine Pointe was not material to group accounts. They said Middle East-related restructuring in H1 was around CHF 8 million, the full-year restructuring outlook remains within CHF 20 million to CHF 40 million, and North America’s strength came from nondestructive testing, energy, aerospace/defense, environmental testing, food, and new pharma wins. On leverage, management said 2.2x is expected at year-end, with a long-term preference to stay below 2.0x and ideally back near 1.7x.